Jennison Associates
Jennison Associates has earned a reputation for excellence by fulfilling client investment needs since its founding in 1969.
Business Model:
Revenue: $100M
Employees: 201-500
Rankings
Industries / Tags:
Detailed Jennison Associates Information
Geographic Data
Address: 466 Lexington Ave
City: New York
State: NY
Zip: 10017
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
2,030,572Website Global Rank
10,145Website Monthly Traffic
Twitter Followers
Description
Jennison Associates has earned a reputation for excellence by fulfilling client investment needs since its founding in 1969. Today, the firm manages over $93 billion for institutions and private clients through separately managed accounts and commingled vehicles, including mutual funds through subadvisory relationships.
Contact Phone:
+12124211000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 1/2015 | Aduro BioTech | Series D | 51.4M |
| 10/2005 | Avanir Pharmaceuticals | Post-IPO Equity | 16.2M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 3/2013 | PTC Therapeutics | Private Equity Round | 60M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 4/2015 | Natera | Series F | 0 |
| 6/2021 | Electric Last Mile Solutions | Post-IPO Equity | 0 |
| 4/2014 | Otonomy | Series D | 49M |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 9/2014 | Flex Pharma | Venture Round | 0 |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 9/2018 | Allogene | Convertible Note | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 3/2021 | Field Trip Health | Post-IPO Equity | 0 |
| 6/2021 | Talkspace | Post-IPO Equity | 0 |
| 10/2011 | Puma Biotechnology | Post-IPO Equity | 55M |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 4/2011 | Merrimack Pharmaceuticals | Private Equity Round | 0 |
| 4/2006 | Merrimack Pharmaceuticals | Series E | 0 |
| 8/2006 | ChemoCentryx | Series C | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 6/2021 | Electric Last Mile Solutions | Post-IPO Equity | 0 |
| 6/2021 | Talkspace | Post-IPO Equity | 0 |
| 3/2021 | Field Trip Health | Post-IPO Equity | 0 |
| 1/2021 | Clover Health | Post-IPO Equity | 0 |
| 9/2018 | Allogene Therapeutics | Convertible Note | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 8/2015 | Wave Life Sciences | Series B | 0 |
| 8/2015 | Ovid Therapeutics | Series B | 0 |
| 8/2015 | Editas Medicine | Series B | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
